checkAd
    Amneal Pharmaceuticals Registered (A) Aktie
    6,3500
     
    EUR
    0,00 %
    0,0000 EUR
    Letzter Kurs 15.05.24 Tradegate
    6,2500
     
    EUR
    641 STK
    Geldkurs 08:52:55
    6,3500
     
    EUR
    627 STK
    Briefkurs 08:52:55
    ISIN: US03168L1052 · WKN: A2JLMD · SYM: 2DT · USA

    Neueste Nachrichten

    Amneal Reports First Quarter 2024 Financial Results
    03.05.24 · Business Wire (engl.) · Amneal Pharmaceuticals Registered (A)
    Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
    24.04.24 · Business Wire (engl.) · Amneal Pharmaceuticals Registered (A)
    Amneal Launches PEMRYDI RTU, the First Ready-to-Use Version of Important Oncology Injectable Medicine
    16.04.24 · Business Wire (engl.) · Amneal Pharmaceuticals Registered (A)
    Amneal to Report First Quarter 2024 Results on May 3, 2024
    10.04.24 · Business Wire (engl.) · Amneal Pharmaceuticals Registered (A)
    Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
    28.03.24 · Business Wire (engl.) · Amneal Pharmaceuticals Registered (A)
    Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
    25.03.24 · Business Wire (engl.) · Amneal Pharmaceuticals Registered (A)
    Fokus Aktien mit extremen Handelsvolumen am Freitag, den 01.03.2024
    01.03.24 · wO Chartvergleich · Biotest
    Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
    01.03.24 · Business Wire (engl.) · Amneal Pharmaceuticals Registered (A)
    Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
    27.02.24 · Business Wire (engl.) · Amneal Pharmaceuticals Registered (A)
    Amneal to Participate at Upcoming Investor Conference
    13.02.24 · Business Wire (engl.) · Amneal Pharmaceuticals Registered (A)
    Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
    08.02.24 · globenewswire · Amneal Pharmaceuticals Registered (A)
    Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
    31.01.24 · Business Wire (engl.) · Amneal Pharmaceuticals Registered (A)